AQST - Aquestive Therapeutics Inc Stock Price, Fair Value and News

$4.74-0.08 (-1.66%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AQST Price Action

Last 7 days

-1.9%

Last 30 days

-4.2%

Last 90 days

10.0%

Trailing 12 Months

144.3%

AQST RSI Chart

AQST Valuation

Market Cap

432.2M

Price/Earnings (Trailing)

-12.28

Price/Sales (Trailing)

7.34

EV/EBITDA

-14.19

Price/Free Cashflow

-12.57

AQST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AQST Fundamentals

AQST Revenue

Revenue (TTM)

58.9M

Rev. Growth (Yr)

4.15%

Rev. Growth (Qtr)

-32.62%

AQST Earnings

Earnings (TTM)

-35.2M

Earnings Growth (Yr)

-465.55%

Earnings Growth (Qtr)

-319.27%

AQST Profitability

EBT Margin

-59.58%

Return on Equity

77.48%

Return on Assets

-32.01%

Free Cashflow Yield

-7.95%

AQST Investor Care

Shares Dilution (1Y)

36.56%

Diluted EPS (TTM)

-0.45

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	51.5M	58.4M	58.9M	0
2023	46.5M	46.5M	48.1M	50.6M
2022	52.0M	49.9M	48.1M	47.7M
2021	48.2M	41.9M	46.9M	50.8M
2020	48.7M	59.3M	55.1M	45.8M
2019	56.7M	53.9M	53.0M	52.6M
2018	73.9M	76.7M	62.8M	67.4M
2017	0	0	0	66.9M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

CEO	Mr. Daniel Barber
WEBSITE	aquestive.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	130

Aquestive Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aquestive Therapeutics Inc? What does AQST stand for in stocks?

AQST is the stock ticker symbol of Aquestive Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aquestive Therapeutics Inc (AQST)?

As of Wed Nov 20 2024, market cap of Aquestive Therapeutics Inc is 432.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AQST stock?

You can check AQST's fair value in chart for subscribers.

Is Aquestive Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AQST is over valued or under valued. Whether Aquestive Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aquestive Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AQST.

What is Aquestive Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, AQST's PE ratio (Price to Earnings) is -12.28 and Price to Sales (PS) ratio is 7.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AQST PE ratio will change depending on the future growth rate expectations of investors.